QT Variability Pre and Post Cardioversion - Full Text View

QT Variability Pre and Post Cardioversion (DCCV)

This study is currently recruiting participants.

Verified by Vanderbilt University, April 2009

First Received: April 20, 2009 Last Updated: April 21, 2009 History of Changes

Sponsors and Collaborators:	Vanderbilt University National Institutes of Health (NIH) Wake Forest University
Information provided by:	Vanderbilt University
ClinicalTrials.gov Identifier:	NCT00885391

Purpose

The purpose of this study is to learn whether the chemicals in the blood and urine are different when the heart is atrial fibrillation compared to normal sinus rhythm.

Condition
Atrial Fibrillation

Study Type:	Observational
Study Design:	Cohort, Prospective
Official Title:	QT Variability Pre & Post Cardioversion in Patient's With Atrial Fibrillation

Resource links provided by NLM:

Genetics Home Reference related topics: Brugada syndrome familial atrial fibrillation short QT syndrome

MedlinePlus related topics: Atrial Fibrillation

U.S. FDA Resources

Further study details as provided by Vanderbilt University:

Biospecimen Retention: Samples With DNA

Biospecimen Description:

Estimated Enrollment:	300
Study Start Date:	January 2007
Estimated Primary Completion Date:	January 2012 (Final data collection date for primary outcome measure)

Detailed Description:

Atrial Fibrillation variably activates the renin-angiotensin-aldosterone system (RAAS), stimulates the sympathetic nervous system, generates oxidant stress, produces natriuretic peptides, and increases ventricular rate. These are interrelated responses and the extent to which these or other pathophysiologic responses determine QT interval during and after Atrial Fibrillation (AF) is unknown. In this study, the QT variability is related to those potential markers in patients with AF undergoing elective DC-cardioversion.

Eligibility

Ages Eligible for Study:	21 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

Cardiology Clinic Hospital inpatient

Criteria

Inclusion Criteria:

At least 21 years of age
Scheduled to undergo an elective DC-Cardioversion of atrial fibrillation or atrial flutter at Vanderbilt University Medical Center

Exclusion Criteria:

Undergoing emergent DC-Cardioversion of atrial fibrillation for hemodynamic instability
Undergoing DC-Cardioversion for post-cardiac surgery
Dual chamber pacemakers

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00885391

Contacts

Contact: Rachael Richardson, RN, BSN

615-322-3173

rachael.armstrong@vanderbilt.edu

Locations

United States, Tennessee
Vanderbilt University Medical Center	Recruiting
Nashville, Tennessee, United States, 37232-0575
Principal Investigator: Dawood Darbar, M.D., Ph.D., F.A.C.C.

Sponsors and Collaborators

Vanderbilt University

National Institutes of Health (NIH)

Wake Forest University

Investigators

Principal Investigator:

Dawood Darbar, M.D., Ph.D., F.A.C.C.

Vanderbilt University

More Information

No publications provided

Responsible Party:	Vanderbilt University Medical Center ( Dawood Darbar, M.D., Ph.D., F.A.C.C. )
Study ID Numbers:	060908, RO1-HL085690-01A2
Study First Received:	April 20, 2009
Last Updated:	April 21, 2009
ClinicalTrials.gov Identifier:	NCT00885391 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by Vanderbilt University:

Atrial Fibrillation
Cardioversion
Direct Current Cardioversion
QT Interval

Study placed in the following topic categories:

Heart Diseases
Atrial Fibrillation
Arrhythmias, Cardiac

Additional relevant MeSH terms:

Pathologic Processes
Heart Diseases
Cardiovascular Diseases
Atrial Fibrillation
Arrhythmias, Cardiac

ClinicalTrials.gov processed this record on August 24, 2009